Filtered By:
Cancer: Oral Cancer
Drug: Tamoxifen
This page shows you your search results in order of date.
Order by Relevance | Date
Total 41 results found since Jan 2013.
Oral Health Concerns of Female Breast Cancer Survivors on Adjuvant Endocrine Therapy
CONCLUSIONS: Data analysis showed that female breast cancer survivors taking adjuvant endocrine therapy appear more likely to have oral health issues than those not taking such therapy. Improved awareness of these issues is critical. Assessment and management guidelines to address these oral health issues are needed by health care providers.PMID:37678330 | DOI:10.1097/01.NAJ.0000978924.32557.53
Source: The American Journal of Nursing - September 7, 2023 Category: Nursing Authors: So-Hyun Park Shiela M Strauss Source Type: research
Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study
CONCLUSION: Oral MCT was found to be an effective and well-tolerated regime with good symptomatic control and low-moderate toxicity profile in patients with relapsed and metastatic ovarian cancer. However, 22% of patients showed grade-III/IV thrombocytopenia.PMID:37530237 | DOI:10.4103/ijc.IJC_143_20
Source: Cancer Control - August 2, 2023 Category: Cancer & Oncology Authors: Kamlesh K Harsh Shankar L Jakhar Guncha Maheshwari Rajkumar Nirban Pramila Kumari Surender K Beniwal Neeti Sharma Harvindra S Kumar Source Type: research
Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic
CONCLUSION: OET adherence was significantly reduced during the COVID-19 pandemic in racial/ethnic minority patients with low SES. Patient-centered interventions are necessary to improve OET adherence in these patients.PMID:37380914 | DOI:10.1007/s11096-023-01609-6
Source: Clinical Genitourinary Cancer - June 28, 2023 Category: Cancer & Oncology Authors: Sama Rahimi Onyebuchi Ononogbu Anjana Mohan Daniel Moussa Susan Abughosh Meghana V Trivedi Source Type: research
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Curr Treat Options Oncol. 2023 Apr 15. doi: 10.1007/s11864-023-01082-3. Online ahead of print.ABSTRACTFor high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer (HR + /HER2 - EBC), short- and long-term recurrence risks remain substantial despite local control with surgery and radiation and systemic treatment with chemotherapy and endocrine therapy (ET). Recent trials have provided new strategies for reducing recurrence. The monarchE trial demonstrated that adding 2 years of adjuvant abemaciclib to ET improves invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS). In the Oly...
Source: Cancer Control - April 15, 2023 Category: Cancer & Oncology Authors: Jamie O Brett Erica L Mayer Source Type: research
Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer
Eur J Med Chem. 2023 Mar 30;253:115324. doi: 10.1016/j.ejmech.2023.115324. Online ahead of print.ABSTRACTAlthough endocrine therapies involving pharmaceuticals, such as tamoxifen and aromatase inhibitors, had initially demonstrated good responses in patients with estrogen receptor-positive (ER+) breast cancer, they often led to drug resistance. ER plays a vital role in the progression of metastatic diseases. Fulvestrant, a first generation selective estrogen receptor degrader (SERD), can effectively downregulate the ER protein and inhibit its downstream signaling pathways. However, as the drug needs to be intramuscularly i...
Source: European Journal of Medicinal Chemistry - April 5, 2023 Category: Chemistry Authors: Yunlong Lu Chao Liu Xin Wang Lijuan Liu Zhihao Zhao Zhenlin Liang Yuanhao Liu Zhenfan Wen Qianming Du Wukun Liu Source Type: research
